BiovailBiovail Corporation Earnings Release Income Statement (US$ millions)

200120022003 2Q cumRevenueProduct sales$521.20$646.00$284.60Research and development$14.60$28.40$6.30Co-promotion, royalty and licensing$47.50$113.60$117.80$583.30$788.00$408.70ExpensesCost of good sold$126.00$164.70$48.70Research and development$51.00$52.20$39.80Selling, general and administrative$110.10$165.70$103.10Amortization$44.50$71.50$86.40Write-down of assets$80.50$31.900.0Acquired research and development0.0$167.70$84.20Settlements0.00.0$(34.10)$412.10$653.70$328.10Operating Income (loss)$171.20$134.30$80.60Interest income$2.70$3.60$4.70interest expense$(36.20)$(32.00)$(19.50)Other income0.0$3.40$6.70Debt conversion premiums$(34.90)0.00.0Income(loss) before provision for income taxes$102.80$109.30$72.50Provision for income taxes$15.30$21.50$10.40Net income (loss)$87.50$87.80$62.10

Diluted earning per share$0.58$0.55$0.39

Net income (loss)$87.50$87.80$62.10Add (deduct) certain itemsWrite-down of assets$80.50$31.900.0Acquired research and development0.0$167.70$84.20Other income0.0$(3.40)0.0Debt conversion premiums$34.900.00.0Net income excluding certain items$202.90$284.00$146.30

Diluted earnings per share excluding certain items$1.35$1.77$0.91

AbbottAbbott Labolatories Income Statement (US$ millions)

20012002Net sales$16,285.20$17,684.70Cost of products sold$7,748.40$8,506.30Research & development$1,577.50$1,561.80Acquired in process R&D$1,330.40$107.70Selling, general & administrative$3,734.90$3,978.80Total operating cost and expenses$14,391.20$14,154.60Operating earnings$1,894.00$3,530.10Net interest expense$234.80$205.20Net foreign espense$31.40$74.60(Income) from TAP Pharm, Products Inc. Joint venture$(333.80)$(666.80)Other (income)/expense, net$78.50$243.70Earning before taxes$1,883.10$3,673.40Taxes in earnings$332.80$879.70Net earnings$1,550.30$2,793.70Net earnings excluding acquired in-process R&D and other one-time charges$2,942.80(Note 1)Diluted earnings per common share (US GAAP)$0.99$1.78Diluted earnings per common share excluding acquired in-process R&D and other one-time charges$1.88$2.06Average no of common shares outstanding plus dilutive common stock options$1,566.00$1,573.30Note 1 : Year 2002 excludes a non-cash charge of $0,05 for acquired in-process research and development related to the acquisition of Biocompatibles stent business and Medtronic alliance, $0,06 for one-time charges related to the consent decree with FDA, a $0,09 non-cash charge related to the decline in value of certain equity investments, and $0,08 related to previously announced restructuring expenses. Year 2001 excludes a non-cash charge of $0,56 for acquired in-process research and development, $0,17 for a one-time adjustment to income TAP joint venture, and $0,16 for other one-time charges related to the acquisition of pharmaceutical business of BASF.

CephalonCephalon Inc. Income Statement (US$ millions)20012002RevenuesProduct sales$226.10$465.90Other revenue$35.90$41.00$262.00$506.90Cost and ExpensesCost of product sales$44.90$74.20Research and developent$83.00$128.30Selling, general and administrative$96.20$172.80Merger and integration costs$0.100.0Acquired in-process research and development$20.000.0$244.20$375.30EBITDA (a)$17.80$131.60Depretiation and amortization$(14.40)$(35.50)Debt exchange expense$(52.40)0.0Gain (charge) on early extinguishment of debt$3.00$(7.10)Other income (expense),net$(9.40)$(26.60)Income (loss) before income taxes$(55.40)$62.40Income tax benefit (expense), net0.0$112.60Income before cumulative effect of changing inventory costing method$(55.40)$175.00Cumulative effect of changing inventory costing method from FIFO to LIFO0.0$(3.50)Net income (loss)$(55.40)$171.50Dividend on convertible exchangeable preferred stock$(5.70)0.0Income (loss) applicable to common shares$(61.10)$171.50Basic income (loss) per common shareIncome (loss) per common share excluding cumulative effect of changing inventory method$(1.27)$3.17Cumulative effect of changing inventory costing method0.0$(0.06)$(1.27)$3.11Diluted income (loss) per common shareIncome (loss) per common share excluding the effect of changing inventory method$(1.27)$3.07Cumulative effect of changing inventory costing method0.0$(0.06)$(1.27)$3.01Weighted average number of common shares outstanding$48.30$55.10Weighted average number of common shares outstanding - assuming dilution$48.30$57.00Reconciliation of Income (loss) applicable to common shares to adjusted net income :Income (loss) applicable to common shares$(61.10)$171.50Certain charges :Deferred tax valuation adjustment0.0$(116.70)CNS joint venture (b)0.0$6.50Short-term bridge financing and other merger related expenses$1.600.0Acquired in-process research and development$20.000.0Debt exchange expense$52.400.0(Gain) charge on early extinguishment of debt$(3.00)$7.10Cumulative effect of changing inventory costing method0.0$3.50Adjusted net income$9.90$71.90Basic adjusted net income per common share$0.20$1.31Diluted adjusted net income per common share$0.19$1.26Notes :(a) Earning (loss) before net interest, depreciation, amortization, debt exchange expense, foreign currency exchange, dividends on convertible exchangeable preferred stock and cumulative effect of changing inventory costing method

(b) Includes $3.508.000 from selling, general and administrative expense and $2.973.000 from other expense